Fluorouracil 5% | Calcipotriene 0.005%

Route: Topical application to affected field skin (face, scalp, upper extremities).

Apply both preparations to lesional and perilesional skin twice daily as directed. If supplied as separate preparations, apply them sequentially. Wear gloves during application; wash hands thoroughly afterward. Avoid contact with eyes, lips, and mucous membranes. For daytime application, follow with broad-spectrum SPF 30+ sunscreen. Treated areas should be monitored for expected local inflammatory reactions.

All dosing is prescriber-determined. Based on published clinical trial evidence:

• Standard short course: Apply fluorouracil 5% cream and calcipotriene 0.005% ointment twice daily for 4 consecutive days to the treatment field.
• This 4-day course may be repeated in cycles as clinically indicated by the prescriber.
• Clinical trials have evaluated the face, scalp, and upper extremities as treatment areas.
• The number of treatment cycles and interval between courses is prescriber-determined based on lesion burden and treatment response.

• Fluorouracil 5%: Converted intracellularly to fluorodeoxyuridine monophosphate (FdUMP), which irreversibly inhibits thymidylate synthase, depleting thymidylate and blocking DNA synthesis. Additional RNA disruption occurs via FUTP incorporation. These cytotoxic effects create immunogenic cell death in AK keratinocytes that amplifies the calcipotriene-driven immune response.
• Calcipotriene 0.005%: Binds the vitamin D receptor (VDR) in epidermal keratinocytes, inducing transcription of thymic stromal lymphopoietin (TSLP). TSLP programs dendritic cells to promote CD4+ Th2 T-cell differentiation. Th2 cells release IL-24 and related cytokines that induce apoptosis and autophagy in premalignant keratinocytes. This immune activation may establish tissue-resident memory T-cell (TRM) populations providing durable antitumor surveillance beyond the treatment course.

Clinical Context: Actinic keratoses (AKs) carry a 0.1–20% risk of progression to invasive squamous cell carcinoma (SCC). This combination provides field therapy for patients with multiple AKs on chronically sun-damaged skin. Published clinical trial data demonstrate:

• Complete AK clearance of ~62% with combination vs. ~8% with 5-FU monotherapy.
• AK lesion reduction of ≥87.8% on the face vs. 26.2% with 5-FU alone at week 8.
• Potential durable SCC risk reduction via antitumor TRM induction, with the combination cohort remaining SCC-free over 1500-day follow-up in one study.

Monitoring Considerations:

• Reassess treated areas at 4–8 weeks post-cycle; plan further cycles based on residual lesion burden.
• Expected local reactions (erythema, burning, scaling around AK lesions) should resolve within 4 weeks of course completion; persistent or worsening lesions warrant biopsy.
• Monitor for hypercalcemia symptoms (weakness, nausea, arrhythmia) when large fields are treated, though rare with the 4-day course.
• Ensure women of childbearing potential use effective contraception due to fluorouracil teratogenicity.

Contraindications:

• Pregnancy: fluorouracil is teratogenic (Category X); absolutely contraindicated.
• Known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency: risk of severe 5-FU systemic toxicity even with topical application.
• Hypersensitivity to fluorouracil, calcipotriene, vitamin D analogs, or any excipient.
• Hypercalcemia or calcium metabolism disorders: calcipotriene may exacerbate.
• Application to mucous membranes, periorbital areas, or large occluded body surface areas.

Warnings & Precautions:

• Local inflammatory reactions (erythema, crusting, burning) are expected treatment responses and not a reason for automatic discontinuation unless severe or atypical.
• Limit calcipotriene to recommended surface areas to avoid hypercalcemia; the short 4-day course substantially reduces this risk.
• Both agents increase photosensitivity; advise strict sun avoidance and SPF 30+ sunscreen throughout treatment.
• Women of childbearing potential must use effective contraception.

Drug Interactions:

• Systemic fluorouracil: additive toxicity; do not use concurrently.
• Calcium or vitamin D supplements and thiazide diuretics: additive hypercalcemia risk with calcipotriene.
• Immunosuppressant agents: may attenuate the Th2 immune activation central to calcipotriene's mechanism.

Common Side Effects: Erythema, burning, pruritus, scaling, and crusting localized to AK lesions (expected and indicative of treatment response). Pigmentary changes, scarring, and systemic toxicity are not typically reported with the 4-day course. Hypercalcemia is rare at standard field-treatment doses.

Store at controlled room temperature (20–25°C / 68–77°F). Protect from heat and light. Keep container tightly closed. Do not freeze. Keep out of reach of children and away from pregnant individuals. Use before the beyond-use date (BUD) assigned by Genesis Compounding on the prescription label.

Why is a vitamin D cream combined with 5-FU for actinic keratoses?

Calcipotriene activates the skin's Th2 immune pathway, training immune cells (CD4+ T cells) to recognize and destroy AK cells via IL-24 cytokine release. This complements 5-FU's direct cytotoxic action, producing dramatically better clearance than 5-FU alone and potentially establishing long-lasting antitumor immune memory.

Is a 4-day course truly sufficient?

Yes, according to published clinical trials. The 4-day twice-daily protocol yields superior AK clearance (>87% lesion reduction on the face) compared to a 4-week 5-FU course, with a more manageable side-effect profile. The immune mechanism continues to work after the medication is stopped.

What skin reactions should I expect?

Erythema, burning, and scaling concentrated around AK lesions are expected and indicate an effective treatment response. These reactions typically resolve within 4 weeks of completing the course and do not require discontinuation unless unusually severe.

Is this combination commercially available?

No. This combination is not available as a fixed commercial product and requires compounding. Genesis Compounding prepares it as a prescription-only, patient-specific 503A preparation.

Who should NOT use this combination?

This preparation is contraindicated in pregnancy (fluorouracil is teratogenic), in patients with DPD enzyme deficiency, in those with hypercalcemia, and in anyone with known hypersensitivity to either ingredient. Women of childbearing potential must use effective contraception.